TY - JOUR
T1 - Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
AU - MEMENTO study group and the INSIGHT-preAD study group
AU - Villeneuve, Sarah Christine
AU - Houot, Marion
AU - Cacciamani, Federica
AU - Verrijp, Merike
AU - Dubois, Bruno
AU - Sikkes, Sietske
AU - Epelbaum, Stéphane
AU - Bakardjian, Hovagim
AU - Benali, Habib
AU - Bertin, Hugo
AU - LaurieBoukadida, Joel Bonheur
AU - Boukerrou, Nadia
AU - Cavedo, Enrica
AU - Chiesa, Patrizia
AU - Colliot, Olivier
AU - Dubois, Marion
AU - Gagliardi, Geoffroy
AU - Genthon, Remy
AU - Habert, Marie Odile
AU - Hampel, Harald
AU - Kas, Aurélie
AU - Lamari, Foudil
AU - Levy, Marcel
AU - Lista, Simone
AU - Metzinger, Christiane
AU - Mochel, Fanny
AU - Nyasse, Francis
AU - Poisson, Catherine
AU - Potier, Marie Claude
AU - Revillon, Marie
AU - Santos, Antonio
AU - Andrade, Katia Santos
AU - Sole, Marine
AU - Surtee, Mohmed
AU - Thiebaud de Schotten, Michel
AU - Vergallo, Andrea
AU - Younsi, Nadjia
N1 - Funding Information: Funding: The study was promoted by INSERM in collaboration with ICM , Instituts Hospitalo-Universitaires à ICM , and Pfizer and has received support within the “Investissement d'Avenir” (ANR-10-AIHU-06) program. The study was promoted in collaboration with the “CHU de Bordeaux” (coordination CIC EC7), the promoter of Memento cohort, and funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/ Lilly . This project/research has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 785907 (Human Brain Project SGA2). The funding sources had no role in the study design, data collection, data analysis, or data interpretation. Funding Information: The authors are grateful to Hovagim Bakardjian and Marine Sole who contributed to collect the A-IADL-Q of the INSIGHT-preAD participants. The authors also wish to thank the 318 INSIGHT-preAD volunteers and their informants for their altruism and dedication to research against Alzheimer's disease. Funding: The study was promoted by INSERM in collaboration with ICM, Instituts Hospitalo-Universitaires à ICM, and Pfizer and has received support within the “Investissement d'Avenir” (ANR-10-AIHU-06) program. The study was promoted in collaboration with the “CHU de Bordeaux” (coordination CIC EC7), the promoter of Memento cohort, and funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/Lilly. This project/research has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 785907 (Human Brain Project SGA2). The funding sources had no role in the study design, data collection, data analysis, or data interpretation. Publisher Copyright: © 2019 The Authors
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early-stage AD hinders the development of new therapies as it is difficult to prove their clinical relevance. Methods: We assessed functional changes over three years in 289 elderly memory complainers from the Investigation of Alzheimer's Predictors in subjective memory complainers cohort using the Amsterdam Instrumental-Activities-of-Daily-Living questionnaire (A-IADL-Q). Results: No overall functional decline related to AD imaging markers was evidenced. However, five distinct classes of A-IADL-Q trajectories were identified. The largest class (212 [73.4%]) had stable A-IADL-Q scores over 3 years. A second group (23 [8.0%]) showed a persistent functional decline, higher amyloid load (P =.0005), and lower education (P =.0392). Discussion: The A-IADL-Q identified a subtle functional decline in asymptomatic at-risk AD individuals. This could have important implications in the field of early intervention in AD.
AB - Introduction: Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early-stage AD hinders the development of new therapies as it is difficult to prove their clinical relevance. Methods: We assessed functional changes over three years in 289 elderly memory complainers from the Investigation of Alzheimer's Predictors in subjective memory complainers cohort using the Amsterdam Instrumental-Activities-of-Daily-Living questionnaire (A-IADL-Q). Results: No overall functional decline related to AD imaging markers was evidenced. However, five distinct classes of A-IADL-Q trajectories were identified. The largest class (212 [73.4%]) had stable A-IADL-Q scores over 3 years. A second group (23 [8.0%]) showed a persistent functional decline, higher amyloid load (P =.0005), and lower education (P =.0392). Discussion: The A-IADL-Q identified a subtle functional decline in asymptomatic at-risk AD individuals. This could have important implications in the field of early intervention in AD.
KW - Alzheimer's disease
KW - Amsterdam-IADL
KW - Autonomy
KW - Latent class analysis
KW - Linear mixed model
UR - http://www.scopus.com/inward/record.url?scp=85072989632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072989632&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072989632&origin=inward
U2 - https://doi.org/10.1016/j.trci.2019.08.009
DO - https://doi.org/10.1016/j.trci.2019.08.009
M3 - Article
C2 - 31650012
SN - 2352-8737
VL - 5
SP - 553
EP - 562
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
ER -
